文献速递骨软组织肉瘤与黑色素瘤

III期CheckMate 067研究的健康相关生活质量结果

Health-related quality of life results from the phase III CheckMate 067 study.
PubMed 文献 · Eur J Cancer · 2017-06-23

CheckMate 067研究比较纳武利尤单抗联合伊匹木单抗、纳武利尤单抗单药与伊匹木单抗单药在晚期黑色素瘤中的健康相关生活质量(HRQoL)。联合组和单药组均维持HRQoL,与伊匹木单抗相比未见临床意义的恶化,各亚组结果相似,因任何原因停药者在随访期HRQoL也无临床意义变化。

要点

  • 纳武利尤单抗联合伊匹木单抗及纳武利尤单抗单药均维持HRQoL,与伊匹木单抗相比未见临床意义恶化。
  • 各患者亚组(BRAF突变状态、部分或完全缓解、3/4级治疗相关不良事件、因任何原因或不良事件停药)结果相似。
  • 因任何原因停药者在随访访视期间HRQoL未见临床意义变化。

核心结论

  • 结果进一步支持纳武利尤单抗单药及纳武利尤单抗联合伊匹木单抗在晚期黑色素瘤患者中的临床获益。
  • 各组间3/4级不良事件差异未转化为所报告HRQoL的临床意义差异,这一发现可能在临床实践中有参考价值。

研究设计与样本

  • III期CheckMate 067研究(研究编号NCT01844505)的HRQoL分析,纳入晚期黑色素瘤患者。
  • 在随机人群基础上,还分析了BRAF突变状态、部分或完全缓解、3/4级治疗相关不良事件、因任何原因停药及因不良事件停药等亚组。
  • HRQoL于第1周及每6周周期第5周评估(前6个月),此后每6周一次,并在两次随访访视时评估,使用欧洲癌症研究与治疗组织核心生活质量问卷和EuroQoL五维度问卷。

主要发现

  • 纳武利尤单抗联合伊匹木单抗及纳武利尤单抗单药均维持HRQoL,与伊匹木单抗相比随时间未见临床意义恶化。
  • 各患者亚组结果相似。
  • 因任何原因停药者在随访访视期间HRQoL未见临床意义变化。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as combination therapy on the one hand and nivolumab as monotherapy on the other, have both demonstrated improved efficacy compared with ipilimumab alone in the CheckMate 067 study. However, the combination resulted in a higher frequency of grade 3/4 adverse events (AEs), which could result in diminished health-related quality of life (HRQoL). Here we report analyses of HRQoL for patients with advanced melanoma in clinical trial CheckMate 067. PATIENTS AND METHODS: HRQoL was assessed at weeks 1 and 5 per 6-week cycle for the first 6 months, once every 6 weeks thereafter, and at two follow-up visits using the European Organization for Research and Treatment of Care Core Quality of Life Questionnaire and the EuroQoL Five Dimensions Questionnaire. In addition to the randomised population, patient subgroups, including BRAF mutation status, partial or complete response, treatment-related AEs of grade 3/4, and those who discontinued due to any reason and due to an AE, were investigated. RESULTS: Nivolumab and ipilimumab combination and nivolumab alone both maintained HRQoL, and no clinically meaningful deterioration was observed over time compared with ipilimumab. In addition, similar results were observed across patient subgroups, and no clinically meaningful changes in HRQoL were observed during follow-up visits for patients who discontinued due to any cause. CONCLUSION: These results further support the clinical benefit of nivolumab monotherapy and nivolumab and ipilimumab combination therapy in patients with advanced melanoma. The finding that the difference in grade 3/4 AEs between the arms did not translate into clinically meaningful differences in the reported HRQoL may be relevant in the clinical setting. STUDY NUMBER: NCT01844505.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Schadendorf D, Larkin J, Wolchok J, et al. Health-related quality of life results from the phase III CheckMate 067 study. Eur J Cancer. 2017. PMID: 28651159. doi:10.1016/j.ejca.2017.05.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。